ixekizumab为一种人源性单克隆Ig G抗体,白细胞介素17A与银屑病等严重炎症性疾病密切相关,ixekizumab能够抑制白细胞介素17A的作用。美国FDA已经批准ixekizumab用于斑块状银屑病的治疗。本品常见不良反应包括恶心、注射部位反应、上呼吸道感染、皮肤和口腔真菌感染、鼻炎、结膜炎及炎症性肠病等。 ixekizumab is a human monoclonal Ig G antibody that is closely related to severe inflammatory diseases such as psoriasis, and ixekizumab inhibits interleukin 17A. The U.S. FDA has approved ixekizumab for the treatment of plaque psoriasis. This product common adverse reactions include nausea, injection site reactions, upper respiratory tract infections, skin and oral fungal infections, rhinitis, conjunctivitis and inflammatory bowel disease.